Playback speed
10 seconds
ASCO GI 2023 Results From the TAPUR Study: Pertuzumab + Trastuzumab for Biliary Tract Cancer With ERBB2/3 Amplification, Overexpression, or Mutation
By
ASCO GI 2023 Conference Coverage
FEATURING
Timothy Cannon
By
ASCO GI 2023 Conference Coverage
FEATURING
Timothy Cannon
166 views
February 7, 2023
Comments 0
Login to view comments.
Click here to Login